ResultsIQ

ResultsIQ › Latest results › Supriya Lifescience Limited

Supriya Lifescience Limited Q3 FY26 results deck summary

NSE: SUPRIYA · BSE: 543434

Results deck of 9 Feb 2026, summarised by AI from the filing.

Q3 FY26 revenue ₹2,064.4 cr (+11.2% YoY); European CMO contract expected to generate peak revenue of ₹60 cr/year from FY27.

Key takeaways

  1. Q3 FY26 revenue Revenue ₹2,064.4 cr (Q3 FY25: ₹1,856.5 cr, +11.2%)
  2. CMO guidance European CMO contract expected to generate peak revenue of ₹60 cr/year starting from FY27.
  3. Capacity change Commissioned Module E, boosting capacity by over 55% from 597 KLPD to 932 KLPD.
  4. Growth driver New product launches in Cardio Vascular, ADHD and Liquid Anesthetic, with full impact expected in Q4 FY26.

Original filing on BSE

Supriya Lifescience Limited Q1 FY27 results

As filed: Revenue ₹190 cr (+31% year on year), EBITDA ₹47.5 cr (−7% year on year), PAT ₹24.0 cr (−31% year on year), EBITDA margin 25.0% (−1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹277 cr (+50% year on year), EBITDA ₹97.6 cr (+46% year on year), PAT ₹74.2 cr (+48% year on year), EBITDA margin 35.3% (−111 bps). Score 92 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were above it. EBITDA margin fell 111 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Profit rose ₹24.2 cr on a year ago, more than the ₹13.0 cr it added the year before. Share price after the results: +19.8% in 30 days (Nifty 500: +2.7%).
  • Q3 FY26: Revenue ₹206 cr (+11% year on year), EBITDA ₹72.1 cr (+8% year on year), PAT ₹49.7 cr (+6% year on year), EBITDA margin 34.9% (−111 bps). Score 35 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 111 bps year on year. Share price after the results: −13.3% in 30 days (Nifty 500: −6.9%).
  • Q2 FY26: Revenue ₹200 cr (+20% year on year), EBITDA ₹72.0 cr (+13% year on year), PAT ₹50.0 cr (+9% year on year), EBITDA margin 36.0% (−255 bps). Score 54 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 255 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Revenue rose ₹34.0 cr on a year ago, more than the ₹26.0 cr it added the year before. Share price after the results: −2.4% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹145 cr (−10% year on year), EBITDA ₹51.0 cr (−19% year on year), PAT ₹35.0 cr (−22% year on year), EBITDA margin 35.2% (−396 bps). Score 14 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 396 bps year on year. Revenue fell 21% from last quarter. Revenue rose ₹-16.0 cr on a year ago, against ₹29.0 cr the year before. Share price after the results: −1.3% in 30 days (Nifty 500: +2.2%).
  • Q4 FY25: Revenue ₹184 cr (+16% year on year), EBITDA ₹67.0 cr (+20% year on year), PAT ₹50.0 cr (+35% year on year), EBITDA margin 36.4% (+97 bps). Score 48 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 97 bps year on year. Revenue rose ₹26.0 cr on a year ago, more than the ₹16.0 cr it added the year before. Share price after the results: −6.7% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹186 cr (+33% year on year), EBITDA ₹67.0 cr (+63% year on year), PAT ₹47.0 cr (+57% year on year), EBITDA margin 36.0% (+674 bps). Score 65 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 674 bps year on year. Profit rose ₹17.0 cr on a year ago, against ₹20.0 cr the year before.
  • Q2 FY25: Revenue ₹166 cr (+19% year on year), EBITDA ₹64.0 cr (+100% year on year), PAT ₹46.0 cr (+92% year on year), EBITDA margin 38.6% (+1,000 bps). Score 89 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Supriya Lifescience Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.